Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Headache and Pain|April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Pharmacogenomics|January 22, 2014
Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM studyRaffaele Palmirotta, Piero Barbanti, Giorgia Ludovici, et al.
Journal of Translational Medicine|October 4, 2023
Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trialMassimiliano Caprio, Eleonora Moriconi, Elisabetta Camajani, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 29, 2015
Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group studyGianni Allais, Gennaro Bussone, Vincenzo Tullo, et al.
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 29, 2014
Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without auraGianni Allais, Vincenzo Tullo, Pietro Cortelli, et al.
Headache|December 18, 2020
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
The Journal of Headache and Pain|September 1, 2019
Current and emerging evidence-based treatment options in chronic migraine: a narrative reviewElio Clemente Agostoni, Piero Barbanti, Paolo Calabresi, et al.
Pageof 11